New York, NY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Market Technology Acquisition Corp (Nasdaq: MTAKU) (the “Company”) announced today that, commencing September 17, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “MTAK” and “MTAKW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “MTAKU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and warrants.

About Market Technology Acquisition Corp

Market Technology Acquisition Corp is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company’s strategy allows for an initial business combination in any business or industry or at any stage of its corporate evolution, its primary focus is businesses operating across the global capital markets ecosystem, with particular emphasis on licensed U.S. equities and options clearing businesses and related market infrastructure, and post-trade, brokerage, custody, execution and financial technology platforms. The Company’s management team is anchored by CEO Jonathan Slone, and CFO and COO, Christopher Hayes, supported by a board of directors with extensive industry, operational and capital markets expertise.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s anticipated use of the net proceeds from the offering and search for an initial business combination. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts:
Jonathan Slone
Jslone@mtechak.com
(917) 362-1067

16 September 2026
ANNOUNCEMENT NO. 315

Major shareholder announcement – BlackRock, Inc.         

Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock, Inc., on 14 September 2026, increased its total holding in ChemoMetec A/S to 15.00%, and that the holding thus has reached the 15 per cent limit in Section 38 of the Capital Markets Act.

Additional information

Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80 

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80 

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Nasdaq-listed embodied AI company introduces its operating platform, enterprise deployments and updated market identifiers

LAS VEGAS, Sept. 16, 2026 (GLOBE NEWSWIRE) — MBody AI Ltd. (“MBody AI” or the “Company”) (NASDAQ: MBAI) today announced the completion of its corporate name change from Check-Cap Ltd., establishing a unified public-market identity for MBody AI following the completion of its merger with MBody AI Corp. on August 26, 2026, and a $10.0 million ordinary-share only underwritten public offering on August 27, 2026 (the “Offering”). The Company’s ordinary shares, par value NIS 48.00 per share (“Ordinary Shares”), continue to be listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “MBAI.” The CUSIP number for the Ordinary Shares is M6S83C106.

MBody AI is an embodied artificial intelligence company whose proprietary, hardware-agnostic software platform is designed to help autonomous systems operate and coordinate across real-world physical environments. At the center of MBody AI’s platform is the proprietary MBody AI Orchestrator, a hardware-agnostic software platform designed to serve as an intelligence layer for autonomous systems operating in real-world environments. Its deployed capabilities include AI-driven fleet analysis and optimization, task verification and unified reporting. MBody AI delivers the platform as an AI-driven enterprise solution combining third-party robotic equipment, the MBody AI Orchestrator software, maintenance and ongoing support under multi-year arrangements.

Fleets managed by the MBody AI Orchestrator have cumulatively delivered service across approximately 600 million square feet of large-scale hospitality environments, with a recently announced expansion into outdoor operations through a pilot deployment with a Fortune 500 gaming operator. The Company serves multiple Fortune 500 gaming and hospitality operators and recently announced Mohegan Sun as a customer. The Company operates robot fleets across eleven U.S. states, up from nine in June 2026. The Company is also operating a robot fleet in Canada.

“Completing the merger, offering and name change gives investors a clear public-market identity for MBody AI,” said John Fowler, Chief Executive Officer. “We built MBody AI in live operating environments. Our technology is deployed with Fortune 500 gaming operators, and proven over the past year and approximately 600 million square feet of cumulative operations. Over the past few months, our team has executed to continue expand our U.S. footprint. The capital from our offering will support customer deployments and the continued development of the MBody AI Orchestrator.”

Following the closing of the Merger, the Company’s Standard Industrial Classification has been changed to 7373 (Services – Computer Integrated Systems Design).

Key identifiers:

  • Legal Name: MBody AI Ltd.
  • Ticker: MBAI
  • Exchange: Nasdaq Capital Market
  • Issued and Outstanding Share Count: approximately 15,293,584 (as of September 15, 2026)
  • CUSIP: M6S83C106
  • ISIN: IL0011336851
  • Commission File Number: 001-36848
  • CIK: 0001610590
  • SIC Code: 7373 (Services — Computer Integrated Systems Design)
  • Transfer Agent: Equiniti Trust Company, LLC
  • Former Legal Name: Check-Cap Ltd. (through August 26, 2026)
  • Security Type: Ordinary Shares, par value NIS 48.00
  • Filer Status: Foreign private issuer
  • Reverse Share Split: 1-for-7, effective August 13, 2026

Merger with MBody AI Corp.

The Company, MBody AI Corp., a Nevada corporation, and CC Merger Sub Inc., a wholly-owned subsidiary of the Company (“Merger Sub”), entered into an Agreement and Plan of Merger dated as of September 12, 2025 (the “Merger Agreement”) providing for the merger of Merger Sub with and into MBody AI Corp. (the “Merger”). On August 26, 2026, pursuant to the Merger Agreement, Merger Sub merged with and into MBody AI Corp., with MBody AI Corp. surviving as a wholly owned subsidiary of the Company. Former stockholders of MBody AI Corp. received an aggregate of approximately 12,379,581 Ordinary Shares (the “MBody Shares”), representing approximately 90% of the Company’s outstanding Ordinary Shares immediately following the completion of the Merger and before the closing of the Offering. MBody Shares were issued in a transaction exempt from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and are “restricted securities” within the meaning of Rule 144 under the Securities Act. The MBody Shares may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from registration, and will not be freely tradable unless and until a registration statement covering their resale has been declared effective or an exemption from registration, including Rule 144, becomes available to the holder. A majority of the MBody Shares are subject to lock-up agreements for 180 days from the date of the final prospectus in connection with the Offering, including all MBody Shares held by officers and directors. 

Underwritten Offering

On August 27, 2026, following the completion of the Merger, the Company completed a firm-commitment underwritten public offering of 1,538,462 Ordinary Shares at a public offering price of $6.50 per share, before underwriting discounts and commissions, for gross proceeds of approximately $10.0 million. The Offering consisted of Ordinary Shares only and no warrants, preferred shares, or convertible securities were issued.

As of the date of this press release, there were 15,293,584 Ordinary Shares of the Company issued and outstanding. As of the close of business on September 15, 2026, the market capitalization of the Company was approximately $99 million.

Learn more about MBody AI’s growth trajectory at ir.mbody.ai

About MBody AI Ltd.

MBody AI Ltd. (NASDAQ: MBAI) develops enterprise software that deploys and manages autonomous robot workforces for hospitality and gaming operators. The Company’s proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI counts Fortune 500 operators among its customers.

No Offer

This press release does not constitute an offer to sell or a solicitation of an offer to buy, and shall not constitute an offer, solicitation, or sale in any state, province, territory, or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the requested change to the Company’s industry classification, the anticipated use of proceeds from the Offering, the continued development of the MBody AI Orchestrator and the rollout of multi-brand fleet control, customer deployments and expansion, the expiry of lock-up agreements, continued Nasdaq listing compliance, maintenance of foreign private issuer status, customer concentration, and future capital needs and dilution. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risks described under “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Investor Relations Contact and Media Contact

Investor Relations:
Lytham Partners, LLC
602-889-9700
ir@mbody.ai

Media Contact:
Core IR
ir@mbody.ai

New Partnership Creates an Important New Revenue Opportunity for the Companies 

NEW BRUNSWICK, N.J., Sept. 16, 2026 (GLOBE NEWSWIRE) — Myseum.AI, Inc. (Nasdaq: MYSE) (“Myseum.AI” or the “Company”), a privacy-first agentic AI and social media technology company, today announced that it has partnered with FUJIFILM North America Corporation, a global provider of prints, photo products, and imaging solutions, to bring print-on-demand products to users of the Company’s Picture Party platform. The new service, available later this month, allows users to seamlessly choose and order everything from classic photo prints to mugs, canvas prints, totes, puzzles, coasters, pillows, and hundreds of other customizable products. Unlike most social media platforms, the Picture Party private social network allows users to share and organize high-resolution photos without degrading image quality, making it an ideal platform for a printing partnership with Fujifilm.

“This is an important new revenue opportunity for the Company, and partnering with Fujifilm was an easy decision,” said Darin Myman, CEO of Myseum.AI. “Picture Party was built to keep photos at their highest quality, and Fujifilm is the gold standard for turning those photos into products people treasure. It’s a win for our users and our business.”

Picture Party users will have access to Fujifilm’s state-of-the-art printing services. Features that will be available include:

  • Premium quality: Vibrant, true-to-life colors and stunning detail in every print, powered by Fujifilm’s advanced color science expertise and printing technology.
  • Wide range of products: From classic photo prints to home décor, gifts, and hundreds of other customizable products, Fujifilm offers a diverse selection for every printing need.
  • Full integration: Seamless integration into the Picture Party app workflow lets users select favorite photos, choose products, and place orders without leaving the platform.
  • Fast and reliable service: Fujifilm’s fast turnaround times and reliable delivery ensure prints and products arrive quickly and in perfect condition.

Unlike traditional social media, Picture Party is a privacy-first private social network. Content is shared only within invited groups and is never sold to advertisers or used to train third-party models, giving organizations and families full control over who sees their photos and videos. The Company’s privacy-first agentic AI technology, planned to launch later this year, will help users automatically organize, curate, and relive their shared memories. Picture Party by Myseum.ai is currently available on the iOS App Store and Google Play.

About Myseum.AI, Inc.

Myseum.AI (formerly DatChat Inc.) is a privacy-focused AI and social media technology company developing innovative platforms for secure digital sharing and storage. Its flagship platform, Picture Party, is a next-generation patented instant social networking experience designed to make sharing photos easier, more fun, and more private. The platform enables users to create curated albums, build encrypted galleries with controlled access, personalize their content feeds, and organize collections within a broader digital ecosystem. Picture Party by Myseum.AI is currently available at the iOS App Store and Google Play, with a desktop version expected later this year. For more information, visit myseum.com.

About Fujifilm

FUJIFILM North America Corporation, a marketing subsidiary of FUJIFILM Holdings America Corporation, consists of five operating divisions. The Imaging Division provides consumer and commercial photographic products and services, including silver halide consumables; inkjet consumables; digital printing equipment, along with service and support; personalized photo products fulfillment; film; one-time-use cameras; and the popular instax™ line of instant cameras, smartphone printers, instant film, and accessories. The Electronic Imaging Division markets its GFX System and X Series lines of mirrorless digital cameras, lenses, and accessories to provide a variety of content creation solutions for both still and moving imagery. The Optical Devices Division provides optical lenses for the broadcast, cinematography, closed circuit television, videography, and industrial markets, and also markets binoculars and other optical imaging solutions. The Business Innovation Division offers a full lineup of digital print and toner technologies focused on enabling the digital transformation of businesses and print shops with its offerings of multifunction printers, digital inkjet presses, production toner printers, software, and more. The Industrial Products Division delivers new products derived from Fujifilm technologies including data storage tape products, including OEM and FUJIFILM Ultrium LTO cartridges, desalination solutions, microfilters and gas separation membranes.

For more information, please visit https://www.fujifilm.com/us/en/about/region, go to https://x.com/fujifilmus to follow Fujifilm on X, or go to https://www.facebook.com/FujifilmAmerica to Like Fujifilm on Facebook.

FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.

For further details about our commitment to sustainability and Fujifilm’s Sustainable Value Plan 2030, click here.

FUJIFILM is a registered trademark of FUJIFILM Corporation and its affiliates.

All other trademarks are the property of their respective owners.

© 2026 FUJIFILM North America Corporation and its affiliates. All rights reserved.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact
ir@datchats.com
732-374-3529

California PPE Becomes the First Independent Service Provider in the Southwest to Offer CO₂ Decontamination as Part of a Comprehensive Approach to Reducing Carcinogenic Contaminants in Firefighter PPE

Riverside Facility Now Accepting Fire Department Gear for DualPhase Clean, a UL-Tested Process Demonstrating Removal of up to 90%+ of Heavy Metals and up to 99.9% of VOCs—Well Above NFPA 1850’s 50% Minimum Removal Standard

California PPE will Host an October 14 Open House in Riverside, Giving Fire Departments an Opportunity to See DualPhase CleanTM Technology and Equipment Firsthand

HUNTSVILLE, Ala., Sept. 16, 2026 (GLOBE NEWSWIRE) — Lakeland Industries, Inc. (“Lakeland Fire + Safety” or “Lakeland”) (NASDAQ: LAKE) today announced that its California PPE Recon, Inc. (“California PPE”) subsidiary has completed installation and qualification of the first CO₂ turnout gear cleaning and decontamination system in California at its Riverside facility. California PPE combines responsive, department-focused service with the resources and capabilities of Lakeland Fire + Safety to deliver comprehensive PPE care and advanced decontamination solutions. The new system is now operational and accepting turnout gear from fire departments across the United States.

California PPE

The addition of CO₂ decontamination creates California PPE’s DualPhase CleanTM process, which combines advanced water-based cleaning with CO₂ technology to address a broader range of contaminants. The UL-tested combined cleaning process demonstrated removal of up to 90%+ of heavy metals and up to 99.9% of semi-volatile organic compounds (SVOCs), significantly exceeding NFPA 1850’s 50% minimum removal standard. CO₂ decontamination can also address contaminants that water alone may not fully remove, including tar, oil, diesel and lithium-ion residues. With the system now in service, California PPE becomes the first independent service provider (“ISP”) to bring CO₂ decontamination technology to fire departments in the United States. The CO₂ cleaning and decontamination machine was leased from Tersus Solutions (“Tersus”) under the agreement announced in February 2026.

“California PPE continues to invest in capabilities that help fire departments reduce exposure risks and extend the life of their protective gear,” said Jim Jenkins, President and Chief Executive Officer of Lakeland. “Working with Tersus Solutions to bring the first CO₂ system online in California and pairing it with our advanced wet wash processes gives departments across the United States access to advanced decontamination capabilities that were not previously available to them regionally. California has the largest number of firefighters in the United States, and we are pleased to put this technology to work on their behalf.”

CO₂ can remove up to 98% of polycyclic aromatic hydrocarbons (PAHs), a type of harmful combustion byproducts that can lead to long-term health risks. In addition, the CO₂ process can extend the life and performance of critical protective equipment, and because the gear exits the system dry, the process can help shorten turnaround time and return gear to service faster.

“No single cleaning method is right for every contaminant or every element of firefighter PPE,” said Chris Robbins, Chief Technology Officer at Tersus Solutions. “That is the advantage of the DualPhase approach. By combining advanced water-based cleaning with CO₂ decontamination, California PPE can address a broader range of contaminants and provide departments with a more comprehensive approach to PPE care.”

“Installing a system at California PPE’s Riverside facility means firefighters across the region now have local access to liquid CO₂ decontamination,” said Peter Whitcomb, Chief Executive Officer at Tersus Solutions. “California PPE has built a reputation for doing this work the right way, and this partnership lets them offer their departments a complete gear care program including both water and CO₂ options under one roof instead of shipping items out or leaving them untreated. This is a game changer for turnout gear, and for the equipment that has historically been hardest to clean properly, like helmets, boots, gloves, and station wear.”

California PPE will host an open house at its Riverside facility on October 14, 2026, where fire departments will have the opportunity to see the DualPhase Clean process and the company’s expanded capabilities firsthand, meet the team, and learn more about advanced PPE care. The Riverside facility joins California PPE’s locations in Fresno, California, and Arizona in providing NFPA-compliant cleaning, advanced inspection and repair, turnout gear rentals, and regional pickup and delivery routes.

California PPE is a leading and rapidly expanding UL-certified ISP in the California firefighting services market, one of the largest fire markets in the United States, and provides advanced decontamination, repair, and inspection of firefighting personal protective equipment, along with rental services and sales of cleaning detergents, extractors, and dryers. To learn more about the DualPhase Clean process please visit https://watchmen-services.com/dualphase-clean/.

About Lakeland Fire + Safety

Lakeland Fire + Safety manufactures and sells a comprehensive line of fire services and industrial protective clothing and accessories for the industrial and first responder markets. In addition, we provide decontamination, repair and rental services that complement our fire services portfolio. Our products are sold globally by our in-house sales teams, our customer service group, and authorized independent sales representatives to a strategic global network of selective fire and industrial distributors and wholesale partners. Our authorized distributors supply end users across various industries, including integrated oil, chemical/petrochemical, automobile, transportation, steel, glass, construction, smelting, cleanroom, janitorial, pharmaceutical, and high-tech electronics manufacturers, as well as scientific, medical laboratories, and the utilities industry. In addition, we supply federal, state and local governmental agencies and departments, including fire and law enforcement, airport crash rescue units, the Department of Defense, the Department of Homeland Security and the Centers for Disease Control. Internationally, we sell to a mix of end-users directly and to industrial distributors, depending on the particular country and market. In addition to the United States, sales are made into more than 50 foreign countries, the majority of which were into China, the European Economic Community (“EEC”), Canada, Chile, Argentina, Commonwealth of Independent States (“CIS”) Region, Colombia, Mexico, Ecuador, India, Uruguay, Middle East, Southeast Asia, Australia, Hong Kong and New Zealand.

For more information about Lakeland, please visit the Company’s website at www.lakeland.com.

About California PPE

Located in Riverside, California, California PPE provides comprehensive PPE care and resources for fire departments, including cleaning, inspection, repair, rental PPE, NFPA 1850 training and equipment, and advanced decontamination solutions.

California PPE combines the responsive, department-focused approach of an independent service provider with the resources, technical expertise and broader capabilities of Lakeland Fire + Safety. This combination allows California PPE to deliver personal service at the local level while continuing to invest in technologies and capabilities designed to improve firefighter safety and PPE care. For more information visit https://california-ppe.com/.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release contains estimates, predictions, opinions, goals and other “forward-looking statements” as that phrase is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, references to the Company’s predictions or expectations of future business or financial performance as well as its goals and objectives for future operations, financial and business trends, business prospects, and management’s expectations for earnings, revenues, expenses, inventory levels, capital levels, liquidity levels, or other future financial or business performance, strategies or expectations, including without limitation our plans to deliver comprehensive PPE care and advanced decontamination solutions. All statements, other than statements of historical facts, which address Lakeland’s expectations of sources or uses for capital, or which express the Company’s expectation for the future with respect to financial performance or operating strategies, can be identified as forward-looking statements. Forward-looking statements involve risks, uncertainties and assumptions as described from time to time in press releases and Forms 8-K, registration statements, quarterly and annual reports and other reports and filings filed with the Securities and Exchange Commission or made by management. As a result, there can be no assurance that Lakeland’s future results will not be materially different from those described herein as “believed,” “projected,” “planned,” “intended,” “anticipated,” “can,” “estimated” or “expected,” or other words which reflect the current view of the Company with respect to future events. We caution readers that these forward-looking statements speak only as of the date hereof. The Company hereby expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which such statement is based, except as may be required by law.

Investor Relations
Chris Tyson
Executive Vice President
MZ Group – MZ North America
949-491-8235
LAKE@mzgroup.us 
www.mzgroup.us

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/856a3973-b12e-4b5e-8f19-87a7338ed598

LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. 

Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.

A live webcast of the fireside chat may also be accessed on the Events & Presentations page, located under the Investor Relations section on equilliumbio.com. A replay of the webcast will be available for approximately 45 days following the conference.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

For more information, visit www.equilliumbio.com.

Investor Contact 
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

TOKYO, Sept. 16, 2026 (GLOBE NEWSWIRE) — CTW (Nasdaq: CTW) (“CTW” or “the Company”), a leading game platform company providing global access to web-based games through its flagship platform, G123.jp, today announced that its Chief Financial Officer Patrick Liu will participate in a virtual fireside chat hosted by Aaron Grey, CFA, CPA, Managing Director and Head of Consumer Research at Alliance Global Partners (A.G.P.), on Wednesday, September 23, 2026 at 1:00 p.m. Eastern Time.

Event Details

Date & Time: Wednesday, September 23, 2026 – 1:00 p.m. ET
Host: Aaron Grey, CFA, CPA, Managing Director and Head of Consumer Research, A.G.P.
Webcast Link: https://us02web.zoom.us/webinar/register/WN_71Q43DUfQb2len_40LFQJA

“We appreciate A.G.P. providing this opportunity to engage with investors and discuss CTW’s business and growth strategy,” said Patrick Liu, Chief Financial Officer of CTW. “We look forward to discussing the G123.jp platform, our approach to officially licensed anime IP, the economics of our browser-based gaming model, and our efforts to expand our presence in the United States.”

A replay of the fireside chat will be available following the event on the Investors page of the Company’s website at ctw.inc/investors.

Institutional investors interested in attending or arranging a follow-up meeting with CTW management may contact their A.G.P. representative or CTW Investor Relations at investor@ctw.inc.

About CTW

CTW is a leading game platform company providing global access to web-based, free-to-play games inspired by popular Japanese anime IP, including So I’m a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World’s Strongest – Rebellion Soul, and Queen’s Blade Limit Break. CTW delivers these games through its globally accessible flagship platform, G123.jp, which has accumulated paying users in over 180 countries since its 2018 launch. Founded in Tokyo in 2013, CTW partners with anime and manga IP holders to bring officially licensed titles to players around the world with no downloads or account registration required.

For more information, visit www.ctw.inc or G123.jp.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. CTW may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about CTW’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: CTW’s growth strategies; its future business development, results of operations and financial condition; its ability to distribute successful and engaging games with high “playability” on its platform; its ability to efficiently attract and retain end-users who come to play and make in-game purchases; its ability to achieve positive return on investment on user acquisition efforts; its ability to establish and maintain relationships with game developers; governmental policies and regulations relating to CTW’s industry; and general economic and business conditions globally and in Japan and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in CTW’s filings with the SEC. All information provided in this press release is as of the date of this press release, and CTW undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Contacts

Media Contact:
CTW Press Team
corpcomm@ctw.inc 

Investor Relations Contact:
Patrick Federle | Head of Investor Relations
investor@ctw.inc 

New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS Therapies

MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of its lead candidate PRP against recently reported clinical datasets from leading RAS-targeted programs, including Revolution Medicines’ daraxonrasib (RASONQUE™; RMC-6236) and Erasca’s pan-RAS molecular glue ERAS-0015.

The analysis is intended to clarify two distinct layers of tumor biology. RAS inhibitors block oncogenic RAS signaling and have produced practice-changing clinical results in RAS-mutant pancreatic ductal adenocarcinoma (PDAC) and encouraging activity in RAS-mutant non-small cell lung cancer (NSCLC). PRP, a proprietary fixed-ratio combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen, does not inhibit RAS. Instead, it promotes differentiation of malignant cells toward a more normal phenotype, reverses epithelial-mesenchymal transition (EMT), depletes cancer stem cells (CSCs), and remodels the fibrotic tumor microenvironment (TME).

Propanc believes these mechanisms address residual drivers of resistance, dormancy, and metastasis that can persist after RAS pathway blockade – creating a scientific rationale for combination or sequential use with RAS inhibitors.

A Landmark Moment for RAS-Targeted Therapy

RAS mutations drive approximately 90% of PDAC and roughly 30% of NSCLC. For decades the target was considered undruggable. That landscape has shifted rapidly.

Revolution Medicines – daraxonrasib: In the randomized Phase 3 RASolute 302 trial in previously treated metastatic PDAC, oral once-daily daraxonrasib produced median overall survival (OS) of 13.2 months versus 6.6–6.7 months with investigator’s-choice chemotherapy (hazard ratio 0.40; p < 0.0001), median progression-free survival (PFS) of 7.3 months versus 3.5 months, and an objective response rate (ORR) of approximately 33% versus 12%. The U.S. Food and Drug Administration approved daraxonrasib in August 2026 for pretreated metastatic pancreatic adenocarcinoma. In previously treated RAS-mutant NSCLC, a Phase 1/2 study published in The New England Journal of Medicine reported ORRs of 31–37% across evaluated dose bands; in a docetaxel-naïve subgroup treated at 160–220 mg, confirmed ORR was 42%, disease-control rate 89%, median PFS 8.3 months, and median OS 16.0 months.

Erasca – ERAS-0015: Preliminary Phase 1 monotherapy data from the U.S. AURORAS-1 and China JYP0015M101 trials showed unconfirmed overall response rates (uORR) of 62% in second-line or later KRAS G12X NSCLC at pharmacologically active doses of 16–32 mg once daily, and 75% in the post-checkpoint-inhibitor / platinum 2/3L NSCLC subset. In second-line KRAS G12X PDAC, uORR was 40% at 16–32 mg and 42% at recommended expansion doses of 24–32 mg; a July 2026 update reported a 57% uORR at 8 weeks at the 32 mg recommended expansion dose in 2L+ KRAS G12X PDAC. The program has been generally well tolerated to date, with mostly low-grade treatment-related adverse events and no dose-limiting toxicities reported at disclosed cutoffs. Erasca has described ERAS-0015 as a potentially best-in-class pan-RAS molecular glue and has outlined registration-enabling plans in pancreatic and lung cancers.

These datasets validate RAS as a therapeutically tractable node. They also leave an open clinical question: how to convert high response rates and doubled survival into durable, metastasis-free outcomes when residual mesenchymal and stem-like cells remain.

PRP Preclinical Profile in Advanced PDAC

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, three-times-weekly intravenous PRP achieved:

  • Greater than 90%, mean, tumor-growth inhibition versus vehicle controls (p < 0.001).
  • Marked reduction in metastatic burden in liver and peritoneum.
  • Significant TME remodeling, including decreased cancer-associated fibroblast (CAF) activity, reduced fibrosis, and suppression of EMT markers.
  • Re-sensitization of chemo-resistant PDAC cells to gemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved efficacy.
  • Median overall survival extension of more than 2.5-fold versus controls.

These findings are built on previously reported >85% tumor-growth inhibition, peer-reviewed work on PRP’s effects on PDAC fibroblasts and CSCs, and limited prior compassionate-use experience with related proenzyme formulations that showed signals of prolonged survival and a favorable safety profile with no severe treatment-related adverse events. PRP holds FDA Orphan Drug Designation for pancreatic cancer and is not restricted to a specific RAS genotype.

Important context: PRP efficacy cited here is preclinical. Daraxonrasib and ERAS-0015 data are from human clinical trials. Cross-modality numerical comparisons are directional only and are not head-to-head results.

Comparative Snapshot

Attribute PRP (PPCB) Daraxonrasib ERAS-0015
Modality IV proenzyme combo (trypsinogen + chymotrypsinogen, 1:6) Oral RAS(ON) multi-selective inhibitor Oral pan-RAS molecular glue
Primary node Differentiation / EMT reversal / CSCs / TME Oncogenic RAS(ON) signaling Pan-RAS (KRAS G12X and related)
Evidence stage Preclinical PDAC + limited compassionate use; Phase 1b planned Feb 2027 Phase 3 PDAC (approved Aug 2026); Phase 1/2 NSCLC in NEJM Phase 1 dose-escalation / expansion; registration path outlined
PDAC activity >90% TGI; >2.5× median OS in models; metastasis and fibrosis reduced Ph3 2L: mOS 13.2 vs 6.6–6.7 mo; mPFS 7.3 vs 3.5 mo; ORR ~33% vs ~12% Ph1 2L KRAS G12X: uORR 40–42%; 57% uORR8wk at 32 mg RDE (2L+)
NSCLC activity Not a primary disclosed indication to date Ph1/2 RAS-mutant: ORR 31–37%; docetaxel-naïve subset ORR 42%, mOS 16 mo Ph1 2L+ KRAS G12X: uORR 62%; post-ICI/platinum 2/3L uORR 75%
Genotype limit Not RAS-mutation restricted RAS-mutant tumors (multi-selective, non-G12C-only) RAS / KRAS G12X enriched populations
Resistance biology addressed EMT, CSCs, CAFs, fibrosis, metastasis, chemo-re-sensitization Oncogene-addicted proliferation; adaptive MAPK reactivation remains a known class issue RAS output; combinations (e.g., anti-EGFR) being explored

Sources: Company disclosures & peer-reviewed or conference reports for September 2026. Figures are not from a single comparative trial.

How Reversal of EMT Occurs — and Why It Matters After RAS Blockade

EMT is a developmental program co-opted by carcinomas. When it is activated, epithelial tumor cells lose polarity and adhesion, acquire a mesenchymal, invasive, and stem-like state, and become more resistant to apoptosis, chemotherapy, and targeted agents. In PDAC, EMT is tightly coupled to TGF-β signaling, a dense desmoplastic stroma, CAF activation, and a CSC reservoir that seeds metastasis and late relapse.

Oncogenic RAS feeds this program. KRAS signaling promotes MAPK- and PI3K-dependent transcriptional networks that stabilize EMT transcription factors, loosen cell–cell junctions, and maintain stemness. RAS inhibitors can collapse that upstream drive and produce rapid tumor shrinkage. They do not, by themselves, reliably extinguish cells that have already completed EMT or that reside in a fibrotic niche that limits drug penetration and immune access. Those residual populations are a leading hypothesized source of acquired resistance to RAS-targeted drugs.

PRP acts at a different biological layer:

  • Proenzyme activation and PAR signaling: After intravenous administration, trypsinogen and chymotrypsinogen are activated and engage proteinase-activated receptors (PAR-1 and PAR-2), which are frequently overexpressed on tumor cells. This cascade is associated with reduced TGF-β pathway output — a master inducer of EMT in late-stage cancer.
  • Restoration of an epithelial phenotype: Peer-reviewed studies show PRP increases epithelial adhesion proteins such as E-cadherin and β-catenin and decreases EMT transcription factors. Cells become less motile, more adherent, and more differentiated — the operational definition of EMT reversal (sometimes described as mesenchymal-to-epithelial transition, or MET).
  • Depletion of cancer stem cells: In pancreatic CSC models, PRP reduced ALDH-high cells and surface markers CD44, CD326, and CXCR4; suppressed primary and secondary sphere formation; down-regulated CSC and metastasis gene programs; and impaired tumor engraftment in vivo.
  • TME and fibroblast remodeling: PRP decreased CAF activity and fibrosis in PDAC models. A less desmoplastic stroma can improve drug delivery and reduce TGF-β-driven conversion of non-stem tumor cells into CSCs — a problem that pathway inhibitors alone do not solve.
  • Chemo- and pathway-sensitization: By pushing cells out of a mesenchymal, drug-tolerant state, PRP resensitized chemo-resistant PDAC cells to gemcitabine/nab-paclitaxel at lower doses. The same logic applies to RAS inhibitors: a smaller mesenchymal reservoir should theoretically reduce the probability of adaptive escape.

In short, RAS inhibitors turn the oncogenic engine off. PRP is designed to convert the remaining cells back toward a less dangerous epithelial identity and to dismantle the niche that protects them. The two approaches are biologically orthogonal.

Strategic Implication for RAS Inhibitor Developers

For companies such as Revolution Medicines and Erasca, durability — not only response rate — will define long-term competitive position as multiple RAS agents enter the same PDAC and NSCLC populations. Three practical implications follow from the EMT-reversal thesis:

  • Combination potential: A RAS inhibitor plus an EMT-reversing, CSC-targeting agent could pair rapid cytoreduction with suppression of the cells most likely to seed resistance. PRP’s non-cytotoxic differentiation mechanism and historically benign compassionate-use safety profile make it a candidate for add-on or maintenance designs that RAS companies are already exploring with chemotherapy, anti-EGFR antibodies, and RAS-doublet regimens (for example, zoldonrasib plus daraxonrasib).
  • Post-progression and maintenance use: When tumors adapt to RAS blockade, mesenchymal drift and fibrotic remodeling are common escape routes. An agent that reverses EMT and reduces CAFs could be sequenced after RAS-inhibitor response to lock in epithelial differentiation and limit metastatic outgrowth.
  • Broader eligible population: PRP is not genotype restricted. In mixed RAS-mutant / RAS-wild-type settings, or in tumors that lose RAS dependence after therapy, a differentiation backbone could extend benefit beyond the label of any single RAS agent.

Propanc is not announcing a partnership with Revolution Medicines or Erasca. The Company is putting the mechanistic case on record as it advances PRP into first-in-human development and as the RAS field looks beyond first-generation survival gains.

Clinical Path

Propanc plans to initiate a multicenter, open-label Phase 1b first-in-human study of PRP in February 2027 in up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at sites in Australia. The two-part design will use Bayesian optimal interval dose escalation with backfill, followed by tumor-specific expansion. PRP is planned as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle. GMP manufacture, pharmacokinetics assay validation, and ethics submissions are advancing in parallel.

“RAS inhibitors have rewritten what is possible in pancreatic and RAS-mutant lung cancer. That is a genuine inflection point for patients,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Our thesis is that turning RAS off is necessary but may not be sufficient. The cells that survive RAS blockade are often the mesenchymal, stem-like cells that PRP differentiate and disarm. If that biology holds in the clinic, PRP could help RAS-focused companies convert high response rates into longer, cleaner remissions.”

“EMT is the program that lets a carcinoma leave home, hide, and return,” said Dr. Ralf Brandt, Propanc’s Research & Development Director. “PRP does not compete with daraxonrasib or ERAS-0015 at the GTPase. It reverses the downstream identity change those tumors used to resist almost every class of drug. That is why we see suppression of EMT markers, loss of CSC phenotypes, less fibrosis, fewer metastases, and more than a two-and-a-half-fold survival extension in PDAC models. Those are the exact liabilities a RAS inhibitor leaves on the table.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780

info@propanc.com

Investor Contact:

irteam@propanc.com

Reciprocal partnership pairs the two platforms to accelerate growth on both sides, building on Amaze’s strategic investment in C2

COSTA MESA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze”), a company focused on creator-powered commerce, today announced it is deepening its relationship with C2 Live Inc. (“C2”) (C2Live.co), a creator-first live social platform and subsidiary of C2 Capital Group, Inc., through a new mutual referral partnership. Building on the company’s previously announced strategic investment, the partnership puts Amaze’s and C2’s ecosystems to work for one another — turning a capital relationship into an active, revenue-generating collaboration across both platforms.

Mutual Agency Partnership

The partnership is designed to create new revenue opportunities for creators and audiences across both platforms, including expanded engagement and monetization through cross-promotional initiatives spanning each company’s creator, brand and audience ecosystems. Amaze has built more than 14 million creator storefronts over the course of its history, while C2 has approximately 1.5 million registered users.

Under the arrangement, each company promotes the other across its email lists and product using dedicated affiliate links and codes. Each party earns a 10% fee on revenue from its user and creator base.

Together, the platforms are positioned to capture share of a global creator economy that Goldman Sachs projects will reach approximately $480 billion by 2027.

Management Commentary

“This partnership is about giving creators more ways to turn real-time engagement into income,” said Joel Krutz, Interim Chief Executive Officer of Amaze. “By connecting our infrastructure and tools to C2’s live social platform we’re opening new paths for monetization across both ecosystems.”

“We’re excited to deepen the partnership with Amaze, this gives our users new ways to grow their audiences, and to generate new revenue,” said Lamont Wilcott, Chief Executive Officer of C2.

Amaze intends to provide further information regarding the transaction as appropriate. Investors are encouraged to review Amaze’s filings with the Securities and Exchange Commission at www.sec.gov.

For investor information, please contact IR@amaze.co.
For press inquiries, please contact PR@amaze.co.

About Amaze

Amaze Holdings, Inc. is an end-to-end, creator-powered commerce platform offering tools for brand development, product creation, advanced e-commerce, audience growth and scalable managed services. By helping people turn what they know, create and share into sustainable income, Amaze enables creators to build deeper audience relationships and more flexible paths to a better life. Discover more at www.amaze.co.

About C2

C2 is a creator-first live streaming platform that adds a social layer to live video by connecting creators and audiences through real-time interaction, gamification and community. Its engagement-driven model enables creators to monetize direct audience participation through virtual goods and interactive experiences. With a growing presence across North America and Asia, C2 is developing a broader suite of tools and services designed to support creators in building, engaging and monetizing their audiences. C2 is operated by C2 Live Inc., a subsidiary of C2 Capital Group, Inc. For more information, visit C2Live.co.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). These statements relate to the referral partnership with C2, the strategic investment, and the resulting future business relationship. These statements can be identified by words such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and are based on our current expectations and views concerning future events and developments and their potential effects on us. Some or all of these forward-looking statements may not occur.

Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that the referral partnership does not produce the anticipated creator acquisition or referral revenue; (ii) the incurrence of unexpected costs, liabilities or delays relating to the partnership or the investment; (iii) the occurrence of a material adverse change in the business, assets, or financial condition of C2 Capital; (iv) the risk that the anticipated benefits of the partnership or the investment are not realized on the anticipated timeline, or at all; and (v) risks include the Risk Factors contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025.

Source: Amaze Holdings, Inc.

Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development

MINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Brian Johnson as Director of Quality and Regulatory Affairs. Johnson brings 13 years of medical device quality and regulatory experience, with a proven track record leading quality systems, regulatory activities, audits and product development initiatives. His appointment strengthens Nuwellis’ quality and regulatory capabilities as the Company continues to invest in the expertise needed to advance product development, commercialization and initiatives across the cardiorenal continuum.

“Brian’s experience leading quality and regulatory functions within medical device organizations makes him an important addition to our team,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “As we continue to advance our product portfolio and execute on multiple strategic initiatives, Brian brings the leadership and technical expertise needed to enhance our quality and regulatory capabilities while supporting our focus on innovation and execution.”

Prior to joining Nuwellis, Johnson served as Senior Quality Manager at Baxter/Vantive, providing quality oversight for two research and development facilities supporting 257 engineering and management employees. Previously, he held quality leadership roles at ATL Medical, where he led research and development and manufacturing quality activities and helped reduce monthly customer complaints by 80%. Johnson holds a Master of Science in Regulatory Affairs and Services from St. Cloud State University and a Bachelor of Science in Manufacturing Engineering Technology from Brigham Young University.

In his new role, Johnson will lead Nuwellis’ quality management and regulatory activities, including quality systems, audits, supplier and contract manufacturer oversight, and regulatory compliance. He will work cross-functionally with product development, operations and commercial teams to support product quality and the continued advancement of Nuwellis’ technology portfolio. Johnson will also support continuous improvement initiatives as the Company advances multiple product development programs.

The appointment of Johnson builds on Nuwellis’ continued investment in the expertise needed to support product development and commercialization. The Company has also recently added expertise in medical affairs and engineering, further strengthening its capabilities across clinical development, product innovation, quality and regulatory execution as Nuwellis advances multiple strategic initiatives.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.